抗坏血酸和烟酰胺与利福平和万古霉素对 SCCmec IV 型耐甲氧西林金黄色葡萄球菌(MRSA)的协同抗菌作用。

Access Microbiology Pub Date : 2023-02-03 eCollection Date: 2023-01-01 DOI:10.1099/acmi.0.000475.v4
Abdullah AlSaleh, Mohammed Shahid, Eman Farid, Nermin Kamal, Khalid Bindayna
{"title":"抗坏血酸和烟酰胺与利福平和万古霉素对 SCCmec IV 型耐甲氧西林金黄色葡萄球菌(MRSA)的协同抗菌作用。","authors":"Abdullah AlSaleh, Mohammed Shahid, Eman Farid, Nermin Kamal, Khalid Bindayna","doi":"10.1099/acmi.0.000475.v4","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background.</b> Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. <b>Material and Methods.</b> Two SCC<i>mec</i> type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCC<i>mec</i> typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. <b>Results and Discussion.</b> Synergy (FIC <0.5) was demonstrated for ascorbic acid (1/2 to 1/4 MIC) with rifampicin (1/2 to 1/8 MIC), and also ascorbic acid (1/2 to 1/16 MIC) when associated with vancomycin (1/2 MIC). Similarly, nicotinamide (1/2 to 1/16 MIC) showed a synergistic effect when paired with low concentrations of rifampicin (1/2 to 1/16 MIC), and also (at 1/4 to 1/16 MIC) with vancomycin (1/2 MIC). All reduced MICs due to synergistic combinations demonstrated statistical significance (<i>P</i><0.05). <b>Conclusion.</b> The synergistic activity demonstrated in associating antioxidants with antibiotics shows promise in managing superbugs. However, more research is required to better understand the mechanism of the synergy and for utilization in clinical care.</p>","PeriodicalId":6956,"journal":{"name":"Access Microbiology","volume":"5 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996180/pdf/","citationCount":"0","resultStr":"{\"title\":\"Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCC<i>mec</i> type IV methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).\",\"authors\":\"Abdullah AlSaleh, Mohammed Shahid, Eman Farid, Nermin Kamal, Khalid Bindayna\",\"doi\":\"10.1099/acmi.0.000475.v4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background.</b> Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. <b>Material and Methods.</b> Two SCC<i>mec</i> type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCC<i>mec</i> typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. <b>Results and Discussion.</b> Synergy (FIC <0.5) was demonstrated for ascorbic acid (1/2 to 1/4 MIC) with rifampicin (1/2 to 1/8 MIC), and also ascorbic acid (1/2 to 1/16 MIC) when associated with vancomycin (1/2 MIC). Similarly, nicotinamide (1/2 to 1/16 MIC) showed a synergistic effect when paired with low concentrations of rifampicin (1/2 to 1/16 MIC), and also (at 1/4 to 1/16 MIC) with vancomycin (1/2 MIC). All reduced MICs due to synergistic combinations demonstrated statistical significance (<i>P</i><0.05). <b>Conclusion.</b> The synergistic activity demonstrated in associating antioxidants with antibiotics shows promise in managing superbugs. However, more research is required to better understand the mechanism of the synergy and for utilization in clinical care.</p>\",\"PeriodicalId\":6956,\"journal\":{\"name\":\"Access Microbiology\",\"volume\":\"5 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996180/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Access Microbiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1099/acmi.0.000475.v4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Access Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1099/acmi.0.000475.v4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景。耐甲氧西林金黄色葡萄球菌(MRSA)是一种致病菌,可引发多种人类疾病。许多毒力因素促进了这种细菌的广泛传播。其中一个重要因素就是获得抗生素耐药基因,从而导致治疗方案的可用性和有效性降低。最近有研究表明,抗氧化剂对 MRSA 等超级细菌的显著抗菌效果在配合抗菌治疗时会产生协同效应。本文旨在研究抗坏血酸和烟酰胺与用于抗 MRSA 的抗菌药物的协同作用。材料和方法。本文研究了两株SCCmec IV型MRSA参考菌株(EMRSA-15和USA300)和10株MRSA临床分离株。鉴定后,通过多重 PCR 对 10 株临床分离株进行了 SCCmec 分型。通过棋盘试验评估了抗氧化剂和抗生素的协同作用。根据临床和实验室标准协会(CLSI)M100 指南,通过两倍微量稀释法测定了每种药剂的最低抑菌浓度(MIC)。结果与讨论。协同作用(FIC PC)结论。抗氧化剂与抗生素的协同作用为控制超级细菌带来了希望。然而,要更好地了解协同作用的机制并在临床护理中加以利用,还需要进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCC<i>mec</i> type IV methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCC<i>mec</i> type IV methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCC<i>mec</i> type IV methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA).

Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. Material and Methods. Two SCCmec type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCCmec typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. Results and Discussion. Synergy (FIC <0.5) was demonstrated for ascorbic acid (1/2 to 1/4 MIC) with rifampicin (1/2 to 1/8 MIC), and also ascorbic acid (1/2 to 1/16 MIC) when associated with vancomycin (1/2 MIC). Similarly, nicotinamide (1/2 to 1/16 MIC) showed a synergistic effect when paired with low concentrations of rifampicin (1/2 to 1/16 MIC), and also (at 1/4 to 1/16 MIC) with vancomycin (1/2 MIC). All reduced MICs due to synergistic combinations demonstrated statistical significance (P<0.05). Conclusion. The synergistic activity demonstrated in associating antioxidants with antibiotics shows promise in managing superbugs. However, more research is required to better understand the mechanism of the synergy and for utilization in clinical care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信